Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.
作者信息
Khan Ahsan A, Lip Gregory Y H
机构信息
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.
出版信息
Ann Transl Med. 2017 Dec;5(23):465. doi: 10.21037/atm.2017.09.19.
Abstract
摘要
相似文献
1
Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.心房颤动合并肾功能不全患者的非维生素K拮抗剂口服抗凝药剂量调整
Ann Transl Med. 2017 Dec;5(23):465. doi: 10.21037/atm.2017.09.19.
2
Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.韩国非瓣膜性心房颤动患者中口服抗凝剂的应用。
Int J Clin Pharm. 2019 Dec;41(6):1434-1441. doi: 10.1007/s11096-019-00901-8. Epub 2019 Sep 14.
3
Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.心房颤动卒中后抗凝治疗的三个月风险效益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究
Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
4
[Old and new oral anticoagulants in the management of atrial fibrillation. Hungarian data].[心房颤动管理中的新型与传统口服抗凝剂。匈牙利数据]
Orv Hetil. 2017 Oct;158(39):1545-1549. doi: 10.1556/650.2017.30802.
5
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.接受维生素K拮抗剂治疗或改用非维生素K拮抗剂口服抗凝剂的非瓣膜性心房颤动患者的出血和动脉血栓栓塞风险：一项回顾性配对队列研究。
Lancet Haematol. 2015 Apr;2(4):e150-9. doi: 10.1016/S2352-3026(15)00027-7. Epub 2015 Apr 1.
6
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.非维生素 K 拮抗剂口服抗凝剂与华法林在 III 期心房颤动试验中的净临床获益。
Am J Med. 2015 Sep;128(9):1007-14.e2. doi: 10.1016/j.amjmed.2015.03.034. Epub 2015 Apr 22.
7
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.在 1 年随访期间，接受稳定维生素 K 拮抗剂治疗或换用非维生素 K 拮抗剂口服抗凝剂的心房颤动患者的生活质量和患者满意度：AF 登记处的 PREFER 子研究。
Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21.
8
INADEQUACY OF VITAMIN K ANTAGONIST USE IN PATIENTS WITH ATRIAL FIBRILLATION - OVERVIEW OF EVERYDAY CLINICAL PRACTICE AT THE MERKUR UNIVERSITY HOSPITAL IN ZAGREB, CROATIA.维生素K拮抗剂在心房颤动患者中的应用不足——克罗地亚萨格勒布梅尔库大学医院日常临床实践概述
Acta Clin Croat. 2019 Dec;58(4):744-750. doi: 10.20471/acc.2019.58.04.22.
9
Risky Business: Judging the Use of Non-Vitamin K Antagonist Oral Anticoagulants for Non-Valvular Atrial Fibrillation in Patients with Renal Dysfunction.风险业务：评估肾功能不全患者非维生素K拮抗剂口服抗凝药用于非瓣膜性心房颤动的情况
J Atr Fibrillation. 2018 Oct 31;11(3):2071. doi: 10.4022/jafib.2071. eCollection 2018 Oct-Nov.
10
Atrial fibrillation and chronic kidney disease: focus on rivaroxaban.心房颤动与慢性肾脏病：聚焦于利伐沙班
J Comp Eff Res. 2015 Nov;4(6):651-64. doi: 10.2217/cer.15.44. Epub 2015 Sep 21.
引用本文的文献
1
Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials.直接抗凝剂与传统抗凝剂治疗癌症相关血栓形成的比较：观察性研究与随机临床试验的汇总及交互分析
Ann Transl Med. 2020 Feb;8(4):95. doi: 10.21037/atm.2019.12.152.
本文引用的文献
1
Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial.用于房颤管理的移动健康技术：整合决策支持、教育与患者参与——mAF应用试验
Am J Med. 2017 Dec;130(12):1388-1396.e6. doi: 10.1016/j.amjmed.2017.07.003. Epub 2017 Aug 26.
2
Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry.遵循指南的抗栓治疗可改善心房颤动患者的预后：基于社区的达灵顿心房颤动登记研究的见解
Mayo Clin Proc. 2017 Aug;92(8):1203-1213. doi: 10.1016/j.mayocp.2017.05.023.
3
Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making.心房颤动的卒中预防：过去、现在和未来。比较指南和实际决策。
Thromb Haemost. 2017 Jun 28;117(7):1230-1239. doi: 10.1160/TH16-11-0876. Epub 2017 Jun 9.
4
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.非维生素 K 拮抗剂口服抗凝剂在伴有肾功能障碍的心房颤动患者中的剂量调整。
J Am Coll Cardiol. 2017 Jun 13;69(23):2779-2790. doi: 10.1016/j.jacc.2017.03.600.
5
Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.停止口服抗凝治疗是房颤患者中风和死亡的一个重要危险因素。
Thromb Haemost. 2017 Jun 27;117(7):1448-1454. doi: 10.1160/TH16-12-0961. Epub 2017 Mar 23.
6
Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.非维生素K拮抗剂口服抗凝剂用于心房颤动的批准后观察性研究
JAMA. 2017 Mar 21;317(11):1115-1116. doi: 10.1001/jama.2017.1152.
7
8
Stroke prevention in Atrial Fibrillation.心房颤动的卒中预防
Eur Heart J. 2017 Jan 1;38(1):4-5. doi: 10.1093/eurheartj/ehw584.
9
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.非维生素 K 拮抗剂口服抗凝剂的标签外剂量与不良结局：ORBIT-AF II 注册研究。
J Am Coll Cardiol. 2016 Dec 20;68(24):2597-2604. doi: 10.1016/j.jacc.2016.09.966.
10
"Unreal world" or "real world" data in oral anticoagulant treatment of atrial fibrillation.心房颤动口服抗凝治疗中的“真实世界”或“现实世界”数据。
Thromb Haemost. 2016 Sep 27;116(4):587-9. doi: 10.1160/TH16-08-0658. Epub 2016 Sep 1.
Zotero 插件